McClung, M R <br/><br/>
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Jan 2013 
 - 293-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1433-2965 
<br/><br/><label>Standard No.: </label>10.1007/s00198-012-2056-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Biomarkers--blood<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--administration & dosage<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Etidronic Acid--administration & dosage<br/>Female<br/>Femur--physiopathology<br/>Humans<br/>Lumbar Vertebrae--physiopathology<br/>Middle Aged<br/>Osteoporosis, Postmenopausal--drug therapy<br/>Risedronic Acid<br/>Treatment Outcome